Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from TYK Medicines, Inc. Class H ( (HK:2410) ).
TYK Medicines, Inc. has received a filing notice from the China Securities Regulatory Commission approving its H share full circulation application, enabling the conversion of 4,608,000 unlisted domestic shares held by one shareholder into the same number of H shares. Once the conversion is implemented and listing approval is granted by the Hong Kong Stock Exchange, these newly converted H shares will be tradable on the Main Board, potentially enhancing the company’s share liquidity and broadening its investor base, though the detailed implementation plan is still being finalized and remains subject to additional regulatory procedures.
The most recent analyst rating on (HK:2410) stock is a Hold with a HK$13.50 price target. To see the full list of analyst forecasts on TYK Medicines, Inc. Class H stock, see the HK:2410 Stock Forecast page.
More about TYK Medicines, Inc. Class H
TYK Medicines, Inc. is a joint stock company incorporated in the People’s Republic of China and listed in Hong Kong, operating in the pharmaceutical and biotechnology sector. The company issues H shares on the Main Board of the Hong Kong Stock Exchange, targeting international investors through its H share structure while maintaining a base of domestic shareholders with unlisted shares in the PRC.
Average Trading Volume: 3,152,622
Technical Sentiment Signal: Sell
Current Market Cap: HK$4.96B
Find detailed analytics on 2410 stock on TipRanks’ Stock Analysis page.